Navigation Links
Researchers discover mutations linked to relapse of childhood leukemia
Date:2/3/2013

After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancerthe first time anyone has linked the disease's reemergence to specific genetic anomalies.

The discovery, co-lead by William L. Carroll, MD, director of NYU Langone Medical Center's Cancer Institute, is reported in a study published online February 3, 2013, in Nature Genetics.

"There has been no progress in curing children who relapse, in spite of giving them very high doses of chemotherapy and bone marrow transplants," said Dr. Carroll.

The discovery suggests how scientists may be able to thwart a dangerous form of acute lymphoblastic leukemia, a rapidly progressing blood-borne cancer that strikes about 6,000 people in the United States every year and accounts for more than one in four pediatric cancers. Eventually, such information could help doctors detect the early emergence of chemotherapy-resistant leukemia cells in patients and switch to a different treatment strategy before the disease can fully reassert itself.

In acute lymphoblastic leukemia, abbreviated ALL, the body's bone marrow produces an abnormally large number of lymphocytes, or white blood cells. Improved treatments have increased the overall cure rate to roughly 80 percent. But Dr. Carroll says the prognosis is especially dire for some 20 percent of patients who relapse.

Medical researchers have suspected that the reemergence of disease could be due to drug resistance, but previous efforts had not uncovered any definitive pathway. For the new study, led by Dr. Carroll and graduate student Julia Meyer, researchers at five U.S. institutions spent three years analyzing multiple bone marrow samples from pediatric ALL patients for more clues to the disease's progression.

With the help of the Children's Oncology Group, a multi-institutional clinical trial
'/>"/>

Contact: Christopher Rucas
Christopher.Rucas@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Caught in the act: Researchers capture key moments in cell death
2. Researchers harness nature to produce the fuel of the future
3. U. of Minn. researchers unveil first artificial enzyme created by evolution in a test tube
4. Prehistoric humans not wiped out by comet, says researchers
5. Clemson University researchers to study oil and gas operations impact on Gulf Coast pelicans
6. Researchers find a better way to culture central nervous cells
7. Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
8. In breast cancer metastasis, researchers identify possible drug target
9. Clemson University researchers: What happens to peaches when the chill is gone?
10. Socially isolated rats are more vulnerable to addiction, report researchers
11. UT Dallas researchers awarded $4.3 million to create next-generation technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... significant anti-tumour activity in patients with advanced BRAF ... has progressed after chemotherapy, according to phase II ... Madrid, Spain. , "Reports of lung cancers ... because these mutations may be associated with increased ... author Dr David Planchard, pulmonary oncologist at the ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... 26, 2012   Reportlinker.com announces that a ... its catalogue: Biometrics Market ... TechNavio,s analysts forecast the ... a CAGR of 42.4 percent over the ...
... University of Massachusetts Amherst resource economist Sylvia Brandt, with colleagues ... upward for childhood asthma and for the first time include ... study released this week in the early online version of ... of asthma due to pollution is much higher than past ...
... The Department of Energy,s Pacific Northwest National Laboratory ... that improves research sample analysis to the marketplace. ... PNNL is receiving a 2012 award for Excellence ... network that encourages federal laboratories to transfer lab-developed ...
Cached Biology News:Biometrics Market in India 2010 - 2014 2Asthma rate and costs from traffic-related air pollution are much higher than once believed 2PNNL recognized for technology transfer 2
(Date:9/29/2014)... -- Research and Markets  has announced the addition ... Services, End-User , Application - Global Forecast to 2019" ... global oligonucleotide synthesis market is expected to reach $1,712.1 ... at a CAGR of 9.8% from 2014 to 2019. ... basis of products and services, applications, end users, and ...
(Date:9/29/2014)... batteries are efficient but involve a range of ... (lucerne seed) and pine resin and a clever ... with a highly interesting alternative. Their study will ... ChemSusChem . , ,We think our discovery can ... for the batteries of the future, says Daniel ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... Burnham Securities Inc. ("Burnham"), a financial ... leader in healthcare venture development and strategic transactions ... expand the range of services each company can ... Securities will be supported by a team of ... in healthcare industry to build a healthcare franchise. ...
Breaking Biology Technology:Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Smart, eco-friendly new battery to solve problems 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... MA (July 20, 2011)A consortium led by scientists at the ... world,s most detailed genetic map. A genetic map ... sperm or egg where the DNA from the mother and ... reproductive cell. The biological process whereby this reshuffling occurs is ...
... (Nasdaq: SGMO ) today announced that the company ... July 27, 2011, after the market closes. The press release ... ET, which will be open to the public via telephone ... the financial results and discuss other business matters. ...
... July 20, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. ... its microRNA alliance with GSK, which is focused on ...
Cached Biology Technology:Researchers create the world's most advanced genetic map 2Researchers create the world's most advanced genetic map 3Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... II (Dual-Stage Quadrupole) Thermo Scientific (Part ... in analytical instrumentation, introduces the latest product ... II. Based on the proven reliability and ... GC/MS systems, the DSQ II incorporates the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: